Vistagen Therapeutics, INC

Vistagen Therapeutics announces the appointment of Dr. Douglas J. Williamson, a seasoned neuroscience drug development expert, to its Board of Directors.

Vistagen Therapeutics announced topline results from its PALISADE-4 Phase 3 trial for fasedienol, which did not meet its primary endpoint in the overall population but showed a statistically significant effect in a subpopulation with very severe social anxiety disorder.

Vistagen Therapeutics directors Margaret FitzPatrick and Dr. Joanne Curley have announced they will not stand for re-election at the 2026 Annual Meeting.

Vistagen Therapeutics announced fiscal year 2026 financial results, highlighting progress in its late-stage clinical programs for social anxiety disorder, depression, and menopausal hot flashes, with key trial data expected soon.

Vistagen Therapeutics announced that its fasedienol clinical program has met international ICH E1 safety exposure standards for social anxiety disorder treatment.

Vistagen Therapeutics announces preliminary positive data from the open-label extension of its Phase 3 PALISADE-3 study for fasedienol, showing well-tolerated safety and clinically relevant improvements in social anxiety.

Vistagen Therapeutics reports increased net losses and declining cash reserves, raising going concern doubts and facing a Nasdaq minimum bid price non-compliance notice.

Vistagen Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses and R&D expenses for Q2 2025, alongside a 'substantial doubt' about its ability to continue as a going concern beyond 12 months.

Vistagen Therapeutics reported increased net losses and cash burn, raising substantial doubt about its ability to continue operations beyond the next 12 months, despite advancing its neuroscience pipeline.

Vistagen Therapeutics reports a net loss of $14.1 million for the three months ended December 31, 2024, and provides an update on its clinical-stage neuroscience programs.

Vistagen Therapeutics reports a net loss of $23.7 million for the six months ended September 30, 2024, while advancing its clinical-stage neuroscience programs.

Vistagen Therapeutics reports a net loss of $10.7 million for the first quarter of fiscal year 2025, while maintaining a strong cash position of $108.4 million.

Vistagen Therapeutics reported mixed results for its fasedienol clinical trials, with two Phase 3 trials failing to meet primary endpoints, while also announcing a workforce reduction and continued focus on cash management.

Vistagen Therapeutics, a clinical-stage biopharmaceutical company, reported a significant increase in net losses and cash burn for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite positive clinical progress for its lead drug candidate, fasedienol, and other pipeline assets.

Vistagen Therapeutics reports its fiscal year 2024 results, highlighting progress in its clinical-stage neuroscience pipeline and strategic partnerships.

Douglas J Williamson, a Director of Vistagen Therapeutics, Inc., received 40,826 shares of common stock on July 29, 2026.

Vistagen Therapeutics Chief Legal Officer Reid G. Adler acquired shares under the company's ESPP.

Vistagen Therapeutics' Chief Financial Officer, Nick B. Tressler, acquired shares under the company's Employee Stock Purchase Plan.

Vistagen Therapeutics Chief Medical Officer Angel S. Angelov received a stock option grant for 150,000 shares.

Vistagen Therapeutics Chief Financial Officer, Nick B. Tressler, has acquired stock options under the company's incentive plan.

Vistagen Therapeutics CEO Shawn Singh received a grant of stock options totaling 75,000 shares with an exercise price of $0.5358.

Vistagen Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for September 10, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Vistagen Therapeutics, Inc. has filed definitive additional proxy soliciting materials with the SEC.

Vistagen Therapeutics, Inc. reports significant progress in its fasedienol Phase 3 clinical program for social anxiety disorder, with topline results expected in late 2025 and early 2026, while announcing its upcoming virtual Annual Meeting and a director's retirement.

Vistagen Therapeutics has filed a definitive proxy statement with the SEC.

Vistagen Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on August 26, 2024, highlighting progress in clinical trials and pipeline development.

Vistagen Therapeutics is holding a special meeting to seek stockholder approval for amendments to its equity incentive plan and employee stock purchase plan to increase the number of shares available for issuance.

Janus Henderson Group plc reports 0% beneficial ownership in Vistagen Therapeutics, Inc., signaling a complete divestment of its previous stake.

StemPoint Capital LP, along with its general partner and Michelle Ross, reported a 1.5% beneficial ownership stake in Vistagen Therapeutics, Inc., primarily through warrants.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of 4.71% in VistaGen Therapeutics, Inc. as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.62% beneficial ownership in Vistagen Therapeutics Inc. following an internal realignment.

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly reported a combined beneficial ownership of 9.97% of Vistagen Therapeutics, Inc.'s common stock.

Nantahala Capital Management, LLC and its managing members reported a 9.99% beneficial ownership stake in Vistagen Therapeutics, Inc. as of September 30, 2025.